β-D-GlcpA-(1<*>3)-β-D-GlcpNAc-(1<*>4)-β-D-GlcpA-(1<*>3)-β-D-GlcNAc | 67007-54-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: β-D-GlcpA-(1<*>3)-β-D-GlcpNAc-(1<*>4)-β-D-GlcpA-(1<*>3)-β-D-GlcNAc
• 英文别名: hyaluronan；hyaluronic acid；(2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
• CAS: 67007-54-9
• 化学式: C₂₈H₄₄N₂O₂₃
• 分子量: 776.657
• InChiKey: KIUKXJAPPMFGSW-DNGZLQJQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -7.4
• 重原子数：
  53
• 可旋转键数：
  12
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  400
• 氢给体数：
  14
• 氢受体数：
  23

反应信息

• 作为反应物：
  描述：

  N-(1-(Aminooxy)-2-oxo-7,10,13-trioxa-3-azahexadecan-16-yl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide 、 β-D-GlcpA-(1<*>3)-β-D-GlcpNAc-(1<*>4)-β-D-GlcpA-(1<*>3)-β-D-GlcNAc 在 苯胺 作用下， 以 aq. acetate buffer 为溶剂， 反应 48.0h， 以56%的产率得到
  参考文献：
  名称：

  A quartz crystal microbalance method to study the terminal functionalization of glycosaminoglycans

  摘要：

  QCM-D被证明是一种新颖的方法，用于量化糖胺聚糖的还原端共轭反应产率和稳定性。

  DOI：

  10.1039/c4cc06905f

文献信息

• CHEMICAL DERIVATIVES AND METHODS FOR SYNTHESIZING AND COMPOUNDING CHEMICAL DERIVATIVES RELATED TO CAPSAICIN PALMITATE AND CAPSAICIN PRODRUGS
  申请人：Chorda Pharma, Inc.

  公开号：US20220168259A1

  公开（公告）日：2022-06-02

  Capsaicin compositions and methods for enhancing hydrophobicity of a molecule useful for pharmaceutical applications, including: (1) a prodrug using a linker such as a carbamate between capsaicin with other structures in order to optimize kinetic control of capsaicin cleavage; (2) a prodrug using a linker such as an unsaturated carboxylic ester between capsaicin with other structures in order to optimize kinetic control of capsaicin cleavage; (3) esters of long-chain fatty acids and capsaicin where hydroxyl groups provide handles for attachment of additional capsaicin molecules; and (4) the use of carboxylic acid diesters to increase overall hydrophobicity of two or more covalently-linked capsaicin molecules. Formulations of palmitated esters of capsaicin are also described, which are designed to enhance hydrophobicity of a molecule useful for pharmaceutical applications, for example to provide compounded mixtures designed to optimize analgesic efficacy.